{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T22:50:14Z","timestamp":1767912614469,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FWO","award":["ID: 1229721N"],"award-info":[{"award-number":["ID: 1229721N"]}]},{"DOI":"10.13039\/501100007660","name":"University of Antwerp","doi-asserted-by":"crossref","award":["FFB210050"],"award-info":[{"award-number":["FFB210050"]}],"id":[{"id":"10.13039\/501100007660","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"DOI":"10.1186\/s13550-024-01188-1","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T10:32:25Z","timestamp":1735295545000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biodistribution and dosimetry of the PET radioligand [18F]CHDI-650 in mice for detection of mutant huntingtin aggregates"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1533-9504","authenticated-orcid":false,"given":"Jordy","family":"Akkermans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5381-015X","authenticated-orcid":false,"given":"Alan","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"Verhaeghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9790-3369","authenticated-orcid":false,"given":"Filipe","family":"Elvas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Zajicek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5097-1361","authenticated-orcid":false,"given":"Jonathan","family":"Bard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3995-0196","authenticated-orcid":false,"given":"Longbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2175-5117","authenticated-orcid":false,"given":"Vinod","family":"Khetarpal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1747-239X","authenticated-orcid":false,"given":"Robert","family":"Doot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3376-0519","authenticated-orcid":false,"given":"Steven","family":"Staelens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4205-5432","authenticated-orcid":false,"given":"Daniele","family":"Bertoglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"key":"1188_CR1","doi-asserted-by":"publisher","unstructured":"Group THsDCR. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72(6):971\u201383.https:\/\/doi.org\/10.1016\/0092-8674(93)90585-E.","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"1188_CR2","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, et al. Huntington disease. Nat Rev Dis Primers. 2015;1:15005. https:\/\/doi.org\/10.1038\/nrdp.2015.5.","journal-title":"Nat Rev Dis Primers."},{"issue":"5","key":"1188_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","volume":"101","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi SJ, Ghosh R, Leavitt BR. Huntingtin lowering strategies for disease modification in Huntington\u2019s disease. Neuron. 2019;101(5):801\u201319. https:\/\/doi.org\/10.1016\/j.neuron.2019.01.039.","journal-title":"Neuron."},{"issue":"10","key":"1188_CR4","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","volume":"16","author":"EJ Wild","year":"2017","unstructured":"Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington\u2019s disease. Lancet Neurol. 2017;16(10):837\u201347. https:\/\/doi.org\/10.1016\/S1474-4422(17)30280-6.","journal-title":"Lancet Neurol."},{"issue":"630","key":"1188_CR5","doi-asserted-by":"publisher","first-page":"eabm3682","DOI":"10.1126\/scitranslmed.abm3682","volume":"14","author":"D Bertoglio","year":"2022","unstructured":"Bertoglio D, Bard J, Hessmann M, Liu L, G\u00e4rtner A, De Lombaerde S, et al. Development of a ligand for in vivo imaging of mutant huntingtin in Huntington\u2019s disease. Sci Transl Med. 2022;14(630):eabm3682. https:\/\/doi.org\/10.1126\/scitranslmed.abm3682.","journal-title":"Sci Transl Med."},{"issue":"4","key":"1188_CR6","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1007\/s00259-021-05578-8","volume":"49","author":"D Bertoglio","year":"2022","unstructured":"Bertoglio D, Verhaeghe J, Miranda A, Wyffels L, Stroobants S, Mrzljak L, et al. Longitudinal preclinical evaluation of the novel radioligand [11C]CHDI-626 for PET imaging of mutant huntingtin aggregates in Huntington\u2019s disease. Eur J Nucl Med Mol Imaging. 2022;49(4):1166\u201375. https:\/\/doi.org\/10.1007\/s00259-021-05578-8.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"1","key":"1188_CR7","doi-asserted-by":"publisher","first-page":"17977","DOI":"10.1038\/s41598-021-97334-z","volume":"11","author":"F Herrmann","year":"2021","unstructured":"Herrmann F, Hessmann M, Schaertl S, Berg-Rosseburg K, Brown CJ, Bursow G, et al. Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates. Sci Rep. 2021;11(1):17977. https:\/\/doi.org\/10.1038\/s41598-021-97334-z.","journal-title":"Sci Rep."},{"issue":"16","key":"1188_CR8","doi-asserted-by":"publisher","first-page":"12003","DOI":"10.1021\/acs.jmedchem.1c00667","volume":"64","author":"L Liu","year":"2021","unstructured":"Liu L, Johnson PD, Prime ME, Khetarpal V, Lee MR, Brown CJ, et al. [(11)C]CHDI-626, a PET tracer candidate for imaging mutant Huntingtin aggregates with reduced binding to AD pathological proteins. J Med Chem. 2021;64(16):12003\u201321. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00667.","journal-title":"J Med Chem."},{"issue":"15","key":"1188_CR9","doi-asserted-by":"publisher","first-page":"8608","DOI":"10.1021\/acs.jmedchem.0c00955","volume":"63","author":"L Liu","year":"2020","unstructured":"Liu L, Prime ME, Lee MR, Khetarpal V, Brown CJ, Johnson PD, et al. Imaging mutant Huntingtin aggregates: development of a potential PET ligand. J Med Chem. 2020;63(15):8608\u201333. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00955.","journal-title":"J Med Chem."},{"issue":"1","key":"1188_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s00259-022-05945-z","volume":"50","author":"A Delva","year":"2022","unstructured":"Delva A, Koole M, Serdons K, Bormans G, Liu L, Bard J, et al. Biodistribution and dosimetry in human healthy volunteers of the PET radioligands [(11)C]CHDI-00485180-R and [(11)C]CHDI-00485626, designed for quantification of cerebral aggregated mutant huntingtin. Eur J Nucl Med Mol Imaging. 2022;50(1):48\u201360. https:\/\/doi.org\/10.1007\/s00259-022-05945-z.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"1188_CR11","first-page":"96","volume":"2","author":"D Bertoglio","year":"2023","unstructured":"Bertoglio D, Weiss AR, Liguore W, Martin LD, Hobbs T, Templon J, et al. In vivo cerebral imaging of mutant huntingtin aggregates using 11C-CHDI-180R PET in a nonhuman primate model of huntington disease. J Nuclear Med. 2023;2:96.","journal-title":"J Nuclear Med."},{"issue":"11","key":"1188_CR12","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.jfluchem.2006.09.015","volume":"127","author":"D Le Bars","year":"2006","unstructured":"Le Bars D. Fluorine-18 and medical imaging: radiopharmaceuticals for positron emission tomography. J Fluorine Chem. 2006;127(11):1488\u201393. https:\/\/doi.org\/10.1016\/j.jfluchem.2006.09.015.","journal-title":"J Fluorine Chem."},{"issue":"1","key":"1188_CR13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1021\/acs.jmedchem.2c01585","volume":"66","author":"L Liu","year":"2023","unstructured":"Liu L, Johnson PD, Prime ME, Khetarpal V, Brown CJ, Anzillotti L, et al. Design and evaluation of [18F]CHDI-650 as a positron emission tomography ligand to image mutant huntingtin aggregates. J Med Chem. 2023;66(1):641\u201356. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01585.","journal-title":"J Med Chem."},{"key":"1188_CR14","first-page":"963","volume":"2","author":"F Zajicek","year":"2024","unstructured":"Zajicek F, Verhaeghe J, De Lombaerde S, Van Eetveldt A, Miranda A, Munoz-Sanjuan I, et al. Preclinical evaluation of the novel [18F]CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington\u2019s disease. Eur J Nucl Med Mol Imag. 2024;2:963.","journal-title":"Eur J Nucl Med Mol Imag."},{"issue":"4","key":"1188_CR15","doi-asserted-by":"publisher","first-page":"045001","DOI":"10.1088\/2057-1976\/ab8c13","volume":"6","author":"A Miranda","year":"2020","unstructured":"Miranda A, Bertoglio D, Glorie D, Stroobants S, Staelens S, Verhaeghe J. Validation of a spatially variant resolution model for small animal brain PET studies. Biomed Phys Eng Express. 2020;6(4):045001. https:\/\/doi.org\/10.1088\/2057-1976\/ab8c13.","journal-title":"Biomed Phys Eng Express."},{"key":"1188_CR16","unstructured":"ICRP. Adult Reference Computational Phantoms. ICRP Publication 110. 2009."},{"issue":"1","key":"1188_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40658-020-00326-7","volume":"7","author":"N Ukon","year":"2020","unstructured":"Ukon N, Zhao S, Washiyama K, Oriuchi N, Tan C, Shimoyama S, et al. Human dosimetry of free 211At and meta-[211At]astatobenzylguanidine (211At-MABG) estimated using preclinical biodistribution from normal mice. EJNMMI Phys. 2020;7(1):58. https:\/\/doi.org\/10.1186\/s40658-020-00326-7.","journal-title":"EJNMMI Phys."},{"issue":"3","key":"1188_CR18","first-page":"247","volume":"16","author":"M Blau","year":"1975","unstructured":"Blau M. Radiation dosimetry of 131I\u201319-iodocholesterol: The Pitfalls of Using Tissue Concentration Data. J Nucl Med. 1975;16(3):247\u20138.","journal-title":"J Nucl Med."},{"key":"1188_CR19","doi-asserted-by":"crossref","unstructured":"ICRP. Basic anatomical and physiological data for use in radiological protection. ICRP publication 89. 2002; 32:1\u2013277, https:\/\/www.icrp.org\/publication.asp?id=ICRP%20Publication%2089.","DOI":"10.1016\/S0146-6453(03)00002-2"},{"key":"1188_CR20","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2967\/jnumed.112.106138","volume":"53","author":"M Stabin","year":"2012","unstructured":"Stabin M, Farmer A. OLINDA\/EXM 2.0: the new generation dosimetry modeling code. J Nucl Med. 2012;53:585.","journal-title":"J Nucl Med."},{"issue":"1","key":"1188_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13550-017-0339-3","volume":"7","author":"M Andersson","year":"2017","unstructured":"Andersson M, Johansson L, Eckerman K, Mattsson S. IDAC-Dose 21, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms. EJNMMI Res. 2017;7(1):88. https:\/\/doi.org\/10.1186\/s13550-017-0339-3.","journal-title":"EJNMMI Res."},{"key":"1188_CR22","unstructured":"ICRP. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007;37(2\u20134):1\u2013332, https:\/\/www.icrp.org\/publication.asp?id=ICRP+Publication+103."},{"issue":"11","key":"1188_CR23","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s00259-013-2512-x","volume":"40","author":"P Zanotti-Fregonara","year":"2013","unstructured":"Zanotti-Fregonara P, Lammertsma AA, Innis RB. Suggested pathway to assess radiation safety of 1\u2078F-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging. 2013;40(11):1781\u20133. https:\/\/doi.org\/10.1007\/s00259-013-2512-x.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"1","key":"1188_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/2191-219X-3-35","volume":"3","author":"F Bretin","year":"2013","unstructured":"Bretin F, Warnock G, Bahri MA, Aerts J, Mestdagh N, Buchanan T, et al. Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H. EJNMMI Research. 2013;3(1):35. https:\/\/doi.org\/10.1186\/2191-219X-3-35.","journal-title":"EJNMMI Research."},{"issue":"2","key":"1188_CR25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11307-016-0992-3","volume":"19","author":"X Zhou","year":"2017","unstructured":"Zhou X, Elsinga PH, Khanapur S, Dierckx RAJO, de Vries EFJ, de Jong JR. Radiation dosimetry of a novel adenosine A2A receptor radioligand [11C]preladenant based on PET\/CT imaging and ex vivo biodistribution in rats. Mol Imag Biol. 2017;19(2):289\u201397. https:\/\/doi.org\/10.1007\/s11307-016-0992-3.","journal-title":"Mol Imag Biol."},{"issue":"3\u20134","key":"1188_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/0146645318756229","volume":"47","author":"M Zankl","year":"2018","unstructured":"Zankl M, Becker J, Lee C, Bolch WE, Yeom YS, Kim CH. Computational phantoms, ICRP\/ICRU, and further developments. Ann ICRP. 2018;47(3\u20134):35\u201344. https:\/\/doi.org\/10.1177\/0146645318756229.","journal-title":"Ann ICRP."},{"issue":"11","key":"1188_CR27","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.2967\/jnumed.112.106138","volume":"53","author":"MG Stabin","year":"2012","unstructured":"Stabin MG, Xu XG, Emmons MA, Segars WP, Shi C, Fernald MJ. RADAR reference adult, pediatric, and pregnant female phantom series for internal and external dosimetry. J Nucl Med. 2012;53(11):1807\u201313. https:\/\/doi.org\/10.2967\/jnumed.112.106138.","journal-title":"J Nucl Med."},{"issue":"3","key":"1188_CR28","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S0168-9002(03)01368-8","volume":"506","author":"S Agostinelli","year":"2003","unstructured":"Agostinelli S, Allison J, Amako K, Apostolakis J, Araujo H, Arce P, et al. Geant4\u2014a simulation toolkit. Nuclear Inst Methods Phys Res Section A. 2003;506(3):250\u2013303. https:\/\/doi.org\/10.1016\/S0168-9002(03)01368-8.","journal-title":"Nuclear Inst Methods Phys Res Section A."},{"issue":"2","key":"1188_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/0146645316661077","volume":"45","author":"WE Bolch","year":"2016","unstructured":"Bolch WE, Jokisch D, Zankl M, Eckerman KF, Fell T, Manger R, et al. ICRP Publication 133: the ICRP computational framework for internal dose assessment for reference adults: specific absorbed fractions. Ann ICRP. 2016;45(2):5\u201373. https:\/\/doi.org\/10.1177\/0146645316661077.","journal-title":"Ann ICRP."},{"key":"1188_CR30","unstructured":"Nelson WR, Hirayama H, Rogers DWO. EGS4 code system. United States; 1985. Report No.: \"SLAC-0265, SLAC-265, SLAC-R-0265, SLAC-R-265\", Contract No.: SLAC-265; ON: DE86007398."},{"key":"1188_CR31","unstructured":"Solutions HM. OLINDA\/EXM Handbook 2021."},{"issue":"1","key":"1188_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40658-018-0219-6","volume":"5","author":"RK Doot","year":"2018","unstructured":"Doot RK, Dubroff JG, Scheuermann JS, Labban KJ, Cai J, Hsieh CJ, et al. Validation of gallbladder absorbed radiation dose reduction simulation: human dosimetry of [(18)F]fluortriopride. EJNMMI Phys. 2018;5(1):21. https:\/\/doi.org\/10.1186\/s40658-018-0219-6.","journal-title":"EJNMMI Phys."},{"key":"1188_CR33","unstructured":"United States Federal Regulations for Radioactive Drugs for Certain Research Uses (21CFR361.1). Prescription drugs for human use generally recognized as safe and effective and not misbranded: drugs used in research. 2023, https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?FR=361.1."},{"key":"1188_CR34","unstructured":"European Commission. Guidance on medical exposures in medical and biomedical research: Publications Office; 1998."},{"key":"1188_CR35","unstructured":"ICRP. Radiological Protection in Biomedical Research. ICRP Publication 62. 1992;ICRP 22 (3), https:\/\/www.icrp.org\/publication.asp?id=ICRP%20Publication%2062."}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-024-01188-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-024-01188-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-024-01188-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T11:05:13Z","timestamp":1735297513000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-024-01188-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1188"],"URL":"https:\/\/doi.org\/10.1186\/s13550-024-01188-1","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments were approved by the Ethical Committee for Animal Testing (ECD 2019\u201339) at the University of Antwerp (Belgium) and the European Committee Guidelines (decree 2010\/63\/CEE) for the care and use of animals were followed.\u00a0The results of this study were reported in accordance to the ARRIVE guideline.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LL, JB, VK and RD are employed by CHDI Management, Inc. the company that manages the scientific activities of CHDI Foundation, Inc. No other potential conflicts of interest relevant to this article exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}